Basurto L, Saucedo R, Zárate A

Language: Spanish
References: 8
Page: 193-196
PDF size: 124.12 Kb.

ABSTRACT

The objective of the study was to evaluate response to hormonal replacement therapy by use of biochemical bone assays. Twenty postmenopausal women (49 to 55 years of age) with osteopenia received three cycles of valerianate estradiol orally, 2 mg daily, for 21 days followed by 1 week without medication. The elevated levels of osteocalcin, 10.9 ± 1 ng/mL (M±SE), and skeletal alkalin phosphatase 24.5 ± 1.4 U/L, decreased significantly (p ‹ 0.001) to 4.3 ± 0.5 ng/mL and 11.3 ± 1.4 U/L, respectively. In addition, C-telopeptide levels decreased from 2.9 ± 0.2 mg/L to 1.6 ± 0.2 mg/L after treatment. These results may indicate that estrogen replacement therapy normalizes the biochemical markers of bone turnover, which in turn could improve bone remodeling.

REFERENCES

1. Zárate A. Osteoporosis: ¿cuándo se debe ordenar una densitometría? Gac Med Mex 2001;137:91-93.

2. Riggs BL. Overview of osteoporosis. West J Med 1991;154:63-77.

3. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg 2000;82: 1063-1070.

4. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium cross links: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.

5. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clinical Chemistry 1999;45: 1359-1368.

6. Arnaud CD. Osteoporosis: Using bone markers for diagnosis and monitoring. Geriatrics 1996;51: 24-30.

7. Fonseca ME, Mason M, Galvan RE, Pascoe D, Ochoa R, Zárate A. Evaluation of an immuno-enzymetric assay (IEMA) using an automatic system for determination of luteinizing hormone and folli-cles stimulating hormone. Arch Med Res 1997; 28:73-78.

8. Eastell R, Aubrey Blumsohn. The value of biochemical markers of bone turnover in osteo-porosis. J Rheumatol 1997;24:1215-1217.